TRASTUZUMAB EMTANSINE
Manner of administration:Injection
Restriction
Indication: Metastatic (Stage IV) HER2 positive breast cancer
Treatment phase: Initial treatment
Restriction
Indication: Metastatic (Stage IV) HER2 positive breast cancer
Treatment phase: Continuing treatment
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 450 mg | # of repeats: 8 | DPMA: $7,053.40 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Kadcyla
(trastuzumab emtansine 100 mg injection, 1 vial)
|
||||
| Kadcyla
(trastuzumab emtansine 160 mg injection, 1 vial)
|
||||
Manner of administration:Injection
Restriction
Indication: Metastatic (Stage IV) HER2 positive breast cancer
Treatment phase: Initial treatment
Restriction
Indication: Metastatic (Stage IV) HER2 positive breast cancer
Treatment phase: Continuing treatment
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 450 mg | # of repeats: 8 | DPMA: $6,912.23 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Kadcyla
(trastuzumab emtansine 100 mg injection, 1 vial)
|
||||
| Kadcyla
(trastuzumab emtansine 160 mg injection, 1 vial)
|
||||
Manner of administration:Injection
Restriction
Indication: Early HER2 positive breast cancer
Treatment phase: Initial adjuvant treatment
Restriction
Indication: Early HER2 positive breast cancer
Treatment phase: Continuing adjuvant treatment
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 450 mg | # of repeats: 6 | DPMA: $6,912.23 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Kadcyla
(trastuzumab emtansine 100 mg injection, 1 vial)
|
||||
| Kadcyla
(trastuzumab emtansine 160 mg injection, 1 vial)
|
||||
Manner of administration:Injection
Restriction
Indication: Early HER2 positive breast cancer
Treatment phase: Initial adjuvant treatment
Restriction
Indication: Early HER2 positive breast cancer
Treatment phase: Continuing adjuvant treatment
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 450 mg | # of repeats: 6 | DPMA: $7,053.40 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Kadcyla
(trastuzumab emtansine 100 mg injection, 1 vial)
|
||||
| Kadcyla
(trastuzumab emtansine 160 mg injection, 1 vial)
|
||||